Immune checkpoint inhibitors in cancer therapy: a focus on T‐regulatory cells
- 17 November 2017
- journal article
- review article
- Published by Wiley in Immunology & Cell Biology
- Vol. 96 (1), 21-33
- https://doi.org/10.1111/imcb.1003
Abstract
Regulatory T cells (Tregs) play essential roles in immune homeostasis; however, their role in tumor microenvironment (TME) is not completely evident. Several studies reported that infiltration of Tregs into various tumor tissues promotes tumor progression by limiting antitumor immunity and supporting tumor immune evasion. Furthermore, in TME, Tregs include heterogeneous subsets of cells expressing different immunosuppressive molecules favoring tumor progression. For an effective cancer therapy, it is critical to understand the Treg heterogeneity and biology in the TME. Recent studies have shown that immune checkpoint molecules promote cancer progression through various antitumor inhibitory mechanisms. Recent advances in cancer immunotherapy have shown the promising potentials of immune checkpoint inhibitors (ICIs) in inducing antitumor immune responses and clinical benefits in patients with cancer at late stages. Most studies revealed the effect of ICIs on T effector cells, and little is known about their effect on Tregs. In this review, we highlight the effects of the ICIs, including anti-CTLA-4, anti-PD-1/PD-L1, anti-LAG-3, anti-TIM-3, and anti-TIGIT, on tumor-infiltrating and peripheral Tregs to elicit effector T-cell functions against tumors. Additionally, we discuss how ICIs may target Tregs for cancer immunotherapy.Keywords
This publication has 110 references indexed in Scilit:
- Targeting Regulatory T Cells in CancerCancer Research, 2011
- PD-1 regulates germinal center B cell survival and the formation and affinity of long-lived plasma cellsNature Immunology, 2010
- PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumorsProceedings of the National Academy of Sciences of the United States of America, 2010
- Intraepithelial Effector (CD3+)/Regulatory (FoxP3+) T-Cell Ratio Predicts a Clinical Outcome of Human Colon CarcinomaGastroenterology, 2009
- PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4+CD25Hi regulatory T cellsInternational Immunology, 2009
- A novel molecular interaction for the adhesion of follicular CD4 T cells to follicular DCEuropean Journal of Immunology, 2009
- How regulatory T cells workNature Reviews Immunology, 2008
- PD-1 and Its Ligands in Tolerance and ImmunityAnnual Review of Immunology, 2008
- LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systemsJCI Insight, 2007
- Programmed Death-1 Ligand 1 Interacts Specifically with the B7-1 Costimulatory Molecule to Inhibit T Cell ResponsesImmunity, 2007